ATR inhibitor RP-3500 demonstrates safety and early clinical benefit | MD Anderson Cancer Center
Cancers | Free Full-Text | Targeting the ATR-CHK1 Axis in Cancer Therapy | HTML
Progress towards a clinically-successful ATR inhibitor for cancer therapy - ScienceDirect
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models | Nature Communications
Ceralasertib (AZD6738) | ≥99%(HPLC) | Selleck | ATM/ATR inhibitor
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors - European Urology
Progress towards a clinically-successful ATR inhibitor for cancer therapy - ScienceDirect
Schematic model for how dual inhibition of IGF-1R and ATR leads to... | Download Scientific Diagram
Studies confirm the clinical potential of ATR inhibitors
Summary of ATR inhibitor-based clinical trials | Download Scientific Diagram
Analysis Reveals Genomic Effects of a New Cancer Treatment Now in Clinical Trials - Penn Medicine
Frontiers | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer | Oncology
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer - ScienceDirect
ATR inhibitor AZD6738 potentiates anti-proliferation of WEE1 inhibitor... | Download Scientific Diagram
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Physician VideoLink
IJMS | Free Full-Text | PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness | HTML
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors - European Urology
Preclinical testing of an ATR inhibitor demonstrates improved response to standard therapies for esophageal cancer - Radiotherapy and Oncology
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Medicine
Master of Science in Clinical Investigation | Vanderbilt University
Clinical trial tests ATR inhibitor in difficult-to-treat cancers | VUMC Reporter | Vanderbilt University
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer - Gastroenterology
Progress towards a clinically-successful ATR inhibitor for cancer therapy - ScienceDirect
EMD SERONO | ATRi
Summary of ATR inhibitor-based clinical trials | Download Scientific Diagram
High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells | Blood Cancer Journal
Merck KGaA's ATR cancer drug cleared for further trials after phase 1 trial success -
